Summary (tl;dr)

A nationwide recall has been issued for certain lots of Cetirizine Hydrochloride 5 mg tablets, a common allergy medication, due to potential cross-contamination with ranitidine, a heartburn drug, which could cause life-threatening allergic reactions in sensitive individuals.

Essential Background

Cetirizine hydrochloride is a widely used over-the-counter antihistamine that treats various allergy symptoms and is often sold as a generic version of Zyrtec. Ranitidine, formerly known by the brand name Zantac, is a medication used to reduce stomach acid and treat conditions like acid reflux and ulcers. Concerns about ranitidine in the past have led to its removal from the market due to the presence of a probable human carcinogen.

The Full Story

Unique Pharmaceutical Laboratories, a division of J. B. Chemicals & Pharmaceuticals Ltd., voluntarily initiated a nationwide recall on July 18, 2026, for four lots of its Cetirizine Hydrochloride Tablets USP 5 mg. The recall was prompted by a pharmacy technician's discovery of red dots and discoloration on some tablets, indicating potential cross-contamination with ranitidine. The U.S. Food and Drug Administration (FDA) subsequently published the announcement on July 20, 2026. The affected lots (GY825029, GY825030, GY825031, GY825032) have an expiration date of October 2028 and were distributed nationwide to wholesalers and retailers by Rising Pharma Holdings Inc. To date, no adverse events related to this recall have been reported.

Why It Matters

This recall is significant because individuals with a hypersensitivity to ranitidine could experience serious and potentially life-threatening adverse events, including severe allergic reactions such as anaphylaxis, characterized by symptoms like low blood pressure, difficulty breathing, throat and facial swelling, widespread itching, hives, and loss of consciousness. Consumers who have purchased Cetirizine Hydrochloride Tablets are advised to check their medication and consult with their pharmacy or doctor, especially if they have concerns or experience any related issues.

Geographic Location

• Panoli, Gujarat, India (where Unique Pharmaceutical Laboratories, the recalling company, is based and initiated the voluntary recall)
• United States (nationwide distribution and recall of cetirizine hydrochloride tablets to wholesalers and retailers)